Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ: BIIB )

179.82 -3.65 (-1.99%)
Streaming Delayed Price Updated: 11:31 AM EDT, Oct 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 712,816
Open 184.63
Bid (Size) 179.73 (6)
Ask (Size) 180.20 (6)
Prev. Close 183.47
Today's Range 177.93 - 185.00
52wk Range 181.25 - 268.30
Shares Outstanding 144,000,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Biogen's Q3 Profit Beats Expectations On Lower Multiple Sclerosis Revenues But New Products Offset Losses, Raises Profit Outlook
Biogen's Q2 revenue fell 3% to $2.47 billion exceeding estimates, with adjusted EPS of $4.08. Multiple sclerosis sales dipped, while new products buoyed performance. 
Via Benzinga
Biogen Earnings Top Views; Alzheimer's Drug Leqembi Gaining Momentum
The biotech giant also raised full-year EPS guidance. 
Via Investor's Business Daily

Performance

YTD
-32.83%
-32.83%
1 Month
-7.23%
-7.23%
3 Month
-15.13%
-15.13%
6 Month
-16.29%
-16.29%
1 Year
-24.19%
-24.19%

More News

Read More
BIOGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Biogen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases
From Biogen Inc.
Via GlobeNewswire
Looking Into Biogen's Recent Short Interest
Via Benzinga
The Latest Analyst Ratings For Biogen
Via Benzinga
Looking Into Biogen's Recent Short Interest
Via Benzinga
Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer
From Biogen Inc.
Via GlobeNewswire
Michael McDonnell, Executive Vice President and Chief Financial Officer to Retire in February 2025
From Biogen Inc.
Via GlobeNewswire
Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024
From Biogen Inc.
Via GlobeNewswire
Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Annual Conference
From Biogen Inc.
Via GlobeNewswire
This Setback for Johnson & Johnson Is 1 More Green Light for Eli Lilly's Stock
Via The Motley Fool
Biogen Announces Late Breaker and New Data Presentations at American Society of Nephrology (ASN) Kidney Week 2024
From Biogen Inc.
Via GlobeNewswire
After Series Of Trial Setbacks, Sage Therapeutics To Lay Off One-Third Workforce
Via Benzinga
Topics Workforce
Exposures Layoff
Larimar Therapeutics' New Drug Could Transform Treatment For Rare Neurological Disease, Analyst Sees Over 200% Upside For Stock
Via Benzinga
Exposures Product Safety
Eli Lilly's Alzheimer's Drug Raises Hopes but Faces Regulatory Hurdles in Europe
Via Benzinga
Large-Cap Stocks In Trouble - Sunday, Oct. 13
Via Talk Markets
These 3 Stocks Are Screaming Oversold: Seize the Opportunity
Via MarketBeat
Topics ETFs Earnings
Exposures Financial
Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients
From Biogen Inc.
Via GlobeNewswire
After Disappointing Parkinson's Data, Sage Therapeutics' Dalzanemdor Flunks Mid-Stage Alzheimer's Study
Via Benzinga
New Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMA
From Biogen Inc.
Via GlobeNewswire
Scholar Rock's Muscle Wasting Drug Excels In Pivotal Trial, Plans FDA Submission Next Year
Via Benzinga
Exposures Product Safety
1 Unstoppable Growth Stock Heading to $2 Trillion by 2030
Via The Motley Fool
Biogen Terminates Collaboration With Sage Therapeutics For Neurological Disorder Candidate
Via Benzinga
Biogen/UCB Partnered Autoimmune Disease Candidate Hits Primary Goal In Late-Stage Study, Sets Stage Another Pivotal Trial
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.